
How a phased CRO partnership built on ICH E6(R2) and E6(R3) principles supported a multi-indication biotech portfolio.
Following the merger between INC Research and inVentiv Health, which created a fully integrated biopharmaceutical solutions organization that combined a CRO and CCO, it has been announced that they have changed their brand identity to Syneos Health, Inc. The new brand will combine commercial and clinical solutions to accelerate customer performance.
Read the full release






